Rockville, Maryland — December 4, 2025 — Leads & Copy — NovaBridge Biosciences (Nasdaq: NBP) will present new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025).
Co-developer ABL Bio will present the poster (Abstract #688) by Gerald Falchook, MD, Director of the Sarah Cannon Research Institute (SCRI) at HealthONE Denver, on Wednesday, December 10th at 5:30 PM GMT. Ragistomig is designed to treat patients relapsed or refractory to checkpoint inhibitors.
According to Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge, the Phase 1 dosing study achieved its objective of extending the therapeutic window for ragistomig by defining a new dosing schedule that could provide strong anti-tumor efficacy and a more manageable tolerability profile, including improved hepatic safety. Dennis added that the data builds on Phase 1 data presented at ASCO 2024 and support progression to combination studies.
Sean Fu, PhD, Chief Executive Officer of NovaBridge, said that Ragistomig was designed to deliver new therapeutic options for patients who have developed resistance or relapsed after treatment with checkpoint inhibitors. Fu added that the company is encouraged by advancements and data that will be presented at ESMO-IO and look forward to continuing the program with ABL Bio.
Ragistomig (also known as ABL503) is a differentiated novel bispecific that integrates a single-chain, Fc-silent PD-L1 segment as a tumor engager and 4-1BB segment as a conditional T cell activator. It was developed using ABL Bio’s “Grabody-T” bispecific antibody platform technology to overcome resistance to PD-(L)1 inhibition and stimulate 4-1BB activation only in the presence of PD-L1 expressing tumor cells, to minimize the risk of off-tumor toxicity.
Preclinical studies demonstrated that the bispecific antibody showed better anti-tumor activity than its single-agent components. A Phase 1 dose expansion study (NCT04762641) is currently being conducted in the U.S. and South Korea. The study was designed with a primary endpoint of defining the dose-limiting toxicity and adverse event profile of ragistomig, as well as to observe the objective response rate, pharmacokinetic and immunogenicity profiles and other secondary endpoints. Ragistomig (also known as ABL503) is being jointly developed with ABL Bio.
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The company combines business development expertise with translational clinical development to identify, accelerate, and advance assets. NovaBridge enables transformative therapies to progress rapidly from discovery toward patients.
The Company’s differentiated pipeline is led by givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed and is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) and is currently completing a Phase 2 study for wet AMD. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
ESMO-IO Meeting information:
- Title: Phase 1 Clinical Trial of Ragistomig (ABL503/TJ-L14B: PD-L1 × 4-1BB bispecific antibody) Q6W Dosing Balances Favorable Safety and Sustained Efficacy Through Extended Immunologic Memory and Reinvigoration of CD8+ T Cells
- Abstract #688
- Date and Time: Wednesday, December 10th at 5:30 PM GMT
A copy of the poster will be available here after the session. To review an overview of the Phase 1 dose escalation data, click here.
PJ Kelleher, LifeSci Advisors, +1-617-430-7579, pkelleher@lifesciadvisors.com
NovaBridge Biosciences, +1-240-745-6330, IR@novabridge.com
Source: NovaBridge Biosciences
